Search results
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Motley Fool via Yahoo Finance· 20 hours agoA few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy...
FDA Panel to Consider Which COVID Strain to Target in an Updated Vaccine
MedPage Today· 3 days agoIn the briefing document, the FDA staff gave a brief history of coronavirus vaccines, noting that...
Retiree calls out Sask. gov't for not communicating changes to accessing COVID-19 drug Paxlovid
CBC via Yahoo News· 1 day agoWhen Greg Pletz contracted COVID-19 in mid-May, he called the Saskatchewan 811 HealthLine and was...
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 18 hours agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Motley Fool via Yahoo Finance· 2 days agoIf you've been on the sidelines, now could be a great time to buy the stock. Shares of Pfizer have...
Pfizer's Options Frenzy: What You Need to Know - Pfizer (NYSE:PFE)
Benzinga· 7 days agoInsights into Volume & Open Interest Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer ...
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 6 days agoQ1 Earnings & Sales Top, EPS Guidance Raised Pfizer’s first-quarter results were strong as it beat...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
FOX Business· 5 days agoLorbrena, like Pfizer's Xalkori, is designed to treat cancer with a mutation of a specific gene...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...